Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 441
- Registration Number
- NCT02557035
- Locations
- 🇧🇬
Specialized Hospital for Active Treatment in Oncology, Haskovo, Department of Medical Oncology, Haskovo, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment "Central Onco Hospital", Plovdiv, Department of Medical Oncology, Plovdiv, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment "Serdika", Sofia, Department of Medical Oncology, Sofia, Bulgaria
Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy
- Conditions
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Hospital Federal de Bonsucesso
- Target Recruit Count
- 80
- Registration Number
- NCT02541019
- Locations
- 🇧🇷
Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-03-30
- Target Recruit Count
- 120
- Registration Number
- NCT02484911
- Locations
- 🇨🇳
First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism
- Conditions
- Interventions
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 300
- Registration Number
- NCT02480088
- Locations
- 🇰🇷
Department of Anesthesiology and Pain Medicine and Anesthesia, Seoul, Korea, Republic of
Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Hospital de Base
- Target Recruit Count
- 150
- Registration Number
- NCT02468323
- Locations
- 🇧🇷
Hospital de Base do Distrito Federal, Brasilia, DF, Brazil
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 80
- Registration Number
- NCT02445872
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Dr. Edward Chow
- Target Recruit Count
- 96
- Registration Number
- NCT02388750
- Locations
- 🇨🇦
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Associazione Salentina Angela Serra
- Target Recruit Count
- 134
- Registration Number
- NCT02205164
- Locations
- 🇮🇹
Ospedale Perrino, Brindisi, BR, Italy
🇮🇹A.O. Riuniti Papardo - Piemonte, Messina, ME, Italy
🇮🇹Università-Azienda Policlinico di Bari, Bari, BA, Italy
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 249
- Registration Number
- NCT02135510
- Locations
- 🇳🇱
Tergooiziekenhuizen, Hilversum, Noord Holland, Netherlands
🇳🇱Rijnstate, Arnhem, Netherlands
🇳🇱Medisch Centrum Alkmaar, Alkmaar, Noord-Holland, Netherlands
Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01952626
- Locations
- 🇰🇷
Kyungpook National Hospital, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.